Full Press Release Details
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies.
IMTX
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Key Takeaway: Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies